EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

1,4‐Pyrazolyl‐Containing SAFit‐Analogues are Selective FKBP51 Inhibitors With Improved Ligand Efficiency and Drug‐Like Profile

Vanessa Buffa, Christian Meyners, Wisely Oki Sugiarto, Michael Bauder, Steffen Gaali, Felix Hausch iD

ChemMedChem · 2024

DOI: 10.1002/cmdc.202400264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Vanessa Buffa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry Clemens-Schöpf-Institute, Technical University Darmstadt, Alarich-Weiss Straße 4, 64287, Darmstadt, Germany. Hauptthemen laut MEDLINE: Pyrazoles, Tacrolimus Binding Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: VIP+ grant Fit4Fat.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FK506 binding protein 51 (FKBP51) is an appealing drug target due to its role in several diseases such as depression, anxiety, chronic pain and obesity. Towards this, selectivity versus the close homolog FKBP52 is essential. However, currently available FKBP51‐selective ligands such as SAFit2 are too large and lack drug‐like properties. Here, we present a structure activity relationship (SAR) analysis of the pipecolic ester moiety of SAFit1 and SAFit2, which culminated in the discovery of the 1,4‐pyrazolyl derivative 23 d , displaying a binding affinity of 0.077 μ M for FKBP51, reduced molecular weight (541.7 g/mol), lower hydrophobicity (cLogP=3.72) and higher ligand efficiency (LE=0.25). Cocrystal structures revealed the importance of the 1,4‐ and 1,3,4‐ substitution patterns of the pyrazole ring versus the 1,4,5 arrangement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesTacrolimus Binding ProteinsStructure-Activity RelationshipLigandsHumansMolecular StructureAnimalsDose-Response Relationship, DrugModels, MolecularTacrolimus Binding Protein 5

Stichwörter der Autor:innen

FKBPFKBP51SAFitpyrazoleselective FKBP51 antagonists

Substanzen

PyrazolesTacrolimus Binding ProteinsLigandsTacrolimus Binding Protein 5

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry Clemens-Schöpf-Institute, Technical University Darmstadt, Alarich-Weiss Straße 4, 64287, Darmstadt, Germany.
  • Present address Dr. Michael Bauder, InfectoPharm Arzneimittel und Consilium GmbH, Von-Humboldt-Str.1, 64646, Heppenheim, Germany.
  • Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804, Munich, Germany.
  • Present address Dr. Steffen Gaali, Roche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg.
  • Center for Synthetic Biology, Technical University Darmstadt, Germany.

ORCID-Profile: Felix Hausch

Förderung

  • VIP+ grant Fit4Fat

Zitieren

APA

Buffa, V., Meyners, C., Sugiarto, W. O., Bauder, M., Gaali, S., & Hausch, F. (2024). 1,4‐Pyrazolyl‐Containing SAFit‐Analogues are Selective FKBP51 Inhibitors With Improved Ligand Efficiency and Drug‐Like Profile. ChemMedChem. https://doi.org/10.1002/cmdc.202400264

Vancouver

Buffa V, Meyners C, Sugiarto WO, Bauder M, Gaali S, Hausch F. 1,4‐Pyrazolyl‐Containing SAFit‐Analogues are Selective FKBP51 Inhibitors With Improved Ligand Efficiency and Drug‐Like Profile. ChemMedChem. 2024. doi:10.1002/cmdc.202400264

BibTeX
@article{Buffa2024,
  author = {Buffa, Vanessa and Meyners, Christian and Sugiarto, Wisely Oki and Bauder, Michael and Gaali, Steffen and Hausch, Felix},
  title = {1,4‐Pyrazolyl‐Containing SAFit‐Analogues are Selective FKBP51 Inhibitors With Improved Ligand Efficiency and Drug‐Like Profile},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202400264}
}
Kostenlos starten →